Skip to main content
. 2023 Mar 17;58:101888. doi: 10.1016/j.eclinm.2023.101888

Fig. 2.

Fig. 2

Change in PSPRS score from baseline at week 16. (a) Change in PSPRS score for individual patients (FMT group, n = 34; Placebo group, n = 34) from baseline at week 16. (b) Mean change in PSPRS score from baseline at week 16 for ITT analysis (FMT group, n = 34; Placebo group, n = 34) and PP analysis (FMT group, n = 31; Placebo group, n = 32). The primary outcomes at week 16 between treatment groups were assessed using a mixed-model, repeated-measures analysis with fixed effects of treatment group, time (categorical), treatment group by time interaction, baseline value, and baseline value by time interaction. Two observations in placebo group and 3 observations in FMT group were missing due to participant withdrawal from the study.